| Dear Voornaam
Following the recent news about the UK-EU Northern Ireland deal, were reconfirming our support for Horizon Europe in a cross-organisational statement with other research and business leaders from across the UK and Europe.
We believe association is in the best interest of cancer researchers and patients globally. Thats why were working to drive forward the best possible outcome for global research and innovation and guarantee our research community can continue to play a leading role in European collaborations. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
 LAST CHANCE TO SIGN OUR PETITION Add your name to our petition before 7 March and join over 77 thousand people calling on the Prime Minister to take action to improve the experience and outcomes of people affected by cancer.
Weve united with over 60 cancer charities as One Cancer Voice to urge the UK government to ensure that the cancer content within the Major Conditions Strategy is ambitious, fully funded and incorporates the evidence already provided by the cancer community. We also ask that the government commit to ensuring there is a longer-term strategy for cancer which focuses on transforming cancer research, diagnosis, treatment and patient experience. |
|
|---|
|  FIVE-YEAR ALLIANCE WITH SINGAPORES EXPERIMENTAL DRUG DEVELOPMENT CENTRE Cancer Research Horizons, our innovation engine, has formed an alliance with the A*STAR Experimental Drug Development Centre to drive forward the translation of cancer research into improved treatments for cancer patients.
The alliance will leverage the combined strengths of both organisations in the UK and Singapore to identify novel cancer biology and increase target identification and validation through drug discovery and development programmes.
|
|
|---|
|
|---|
|
|
SHOWCASE YOUR WORK AT OUR RADIATION RESEARCH CONFERENCE Are you an early career scientist working in radiation research? You could be selected to speak alongside a line-up of international scientists including Kaye Williams (The University of Manchester), David Lewis (Cancer Research UK Beatson Institute) and Silvia Formenti (Weill Cornell Medical College).
Submit an abstract by 31 March to be considered for a proffered talk at our new Radiation Research Conference, run in partnership with the Association for Radiation Research.
All abstracts will feature as poster presentations. Poster abstract submissions will close on 7 April. |
|
|---|
|
|---|
|
|
 OUR RESEARCH OUTPUT SUBMISSION WINDOW IS CLOSING SOON You have two weeks left to submit your research outputs if you are a Cancer Research UK-funded researcher or PhD student.
Remember returning a submission is a condition of your grant, and it should take you no more than an hour to complete.
Thank you for helping us monitor our progress. |
|
|---|
|  ABOUT TO PUBLISH YOUR RESEARCH? KEEP US IN THE LOOP Are you preparing a Cancer Research UK-funded research paper for publication? If so, wed love to hear about it.
You can let us know about pending publications via our manuscript notification form. All information will be treated confidentially and wont be used without consulting you first.
Knowing in advance about upcoming publications helps us plan our communications and means we can better talk to our supporters about the work that their donations help fund. |
|
|---|
|
|---|
|
|
 WHY COLOUR BLINDNESS IS A RESEARCH INTEGRITY ISSUE How can you make sure your research papers are accessible to colour blind readers? In his latest blogpost for our series on research integrity, Dr Andrew Porter (Research Integrity and Training Adviser at the Cancer Research UK Manchester Institute) provides tips and resources on how to best showcase your images and data.
Andrew details how using colours in an accessible way not only shows care and respect to all readers, but can also lead to better design and improved communication.
|
|
|---|
|  NEW WORKING GROUPS TO DEVELOP INTERNATIONAL CLINICAL TRIALS International Rare Cancer Initiative invites you to express interest in creating a new working group to boost the progress of new treatments for people with rare cancers.
With collaborators from different countries, disciplines and skills, the working groups will use innovative methodologies to answer research questions and overcome barriers to international trials.
The groups will design, develop and deliver an innovative trial in a rare cancer area within three years.
|
|
|---|
|
|---|
|
|
 PROGRESS YOUR TECHNOLOGY-FOCUSED CANCER INNOVATION Apply to the University of Cambridges IMPULSE programme by 19 March to network and build one-on-one relationships with 120+ mentors, investors and top-tier experienced entrepreneurs to further develop your tech idea or venture.
This three-month hybrid programme is delivered through a combined learning approach including practical workshops, industry mentoring, one-to-one advice with business professionals, pitch sessions, carrying out market research, and networking. |
|
|---|
|  KEEP UP TO DATE WITH ENTREPRENEURIAL OPPORTUNITIES AND NEWS In 2022, Cancer Research Horizons helped deliver nine entrepreneurial programmes and events: Eureka Virtual School, Lean Launch Programme, Cancer Tech Accelerator, Start Codon webinar series, KQ Labs, Edinburgh Venture Builder Incubator, Panacea Oncostars, Oncology Development Programme 2 and the Innovation Summit.
Interested in getting updates on similar opportunities throughout 2023? Sign up to the Cancer Research Horizons entrepreneurial newsletter today.
|
|
|---|
|
|---|
|
|
| | | Manchester, UK 15 March 2023 |
|
|---|
|
|---|
| | | Glasgow, UK 27 April 2023 |
|
|---|
|
|---|
| | | Torino, Italy 12 June 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
